摘要
目的探讨XELOX方案联合腹腔热灌注化疗(HIPEC)对结直肠癌(CRC)手术患者预后的影响。方法72例CRC患者随机分为两组。在根治术后,对照组给予XELOX方案化疗,观察组给予XELOX方案化疗联合HIPEC。比较两组的临床疗效、生存情况和不良反应。结果化疗后,观察组的治疗总有效率、6个月无病生存率均高于对照组(P<0.05)。观察组的骨髓抑制发生率高于对照组,消化道反应发生率低于对照组(P<0.05);两组的肝肾功能损伤发生率比较,差异无统计学意义(P>0.05)。结论XELOX方案联合HIPEC可提高CRC患者的临床疗效,改善患者短期预后,但可能会增加患者的不良反应.
Objective To explore the impact of XELOX regimen combined with hyperthermic intraperitoneal chemotherapy(HIPEC)on the prognosis of patients with colorectal cancer(CRC)surgery.Methods A total of 72 patients with CRC were randomly divided into two groups.After radical resection,the control group was given XELOX chemotherapy,and the observation group was given XELOX chemotherapy combined with HIPEC.The clinical efficacy,survival situation and adverse reactions were compared between the two groups.Results After chemotherapy,the total effective rate and 6-month disease-free survival rate of the observation group were higher than those of the control group(P<0.05).The incidence of bone marrow suppression of the observation group was higher than that of the control group,and the incidence of gastrointestinal reactions was lower than that of the control group(P<0.05);No significant difference was found in the incidence of liver and kidney function injury between the two groups(P>0.05).Conclusions XELOX regimen combined with HIPEC can improve the clinical efficacy and short-term prognosis of CRC patients,but may increase the adverse reactions of patients.
作者
李铁民
高佳美
姚冠航
苗景玉
LI Tiemin;GAO Jiamei;YAO Guanhang;MIAO Jingyu(Department of General Surgery,Luoyang Third People's Hospital,Luoyang 471000,China)
出处
《临床医学工程》
2024年第8期971-972,共2页
Clinical Medicine & Engineering
关键词
XELOX方案
腹腔热灌注化疗
结直肠癌
预后
XELOX regimen
Hyperthermic intraperitoneal chemotherapy
Colorectal cancer
Prognosis
